Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers ...

Investment could rise in 2025 if interest rates decline and the Trump administration is friendly to private equity firms.

Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Trump opened the door for private equity to tap 401(k)s, and now private equity bosses want legal protection. Here's what ...

That “waste-to-value” is increasingly getting quiet attention from private equity and infrastructure investors.

Wall Street is often blamed for reducing corporate managers’ understanding of business to a single, gameable measure of ...

In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...

Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors ...

Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...

Harlem Capital, a high-profile Black-owned private equity firm that launched in 2015 with the backing of TPG, told the FT ...

In 2025’s go-go leveraged debt markets, everything is up for negotiation, but a trio of investor protections are proving to ...